Chardan Capital Maintains Buy on Achilles Therapeutics, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital analyst Geulah Livshits maintains a Buy rating on Achilles Therapeutics (NASDAQ:ACHL) but lowers the price target from $11 to $6.

April 05, 2024 | 10:38 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Chardan Capital maintains a Buy rating on Achilles Therapeutics but lowers the price target from $11 to $6.
The reduction in price target from $11 to $6 by Chardan Capital, despite maintaining a Buy rating, could lead to a negative short-term sentiment among investors. This adjustment reflects a lowered expectation for the stock's performance, which might result in a decrease in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100